Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
Utilization of a UPLC-MS/MS Approach to Elucidate the Role of ABCB1-Mediated Paclitaxel Resistance in Non-Small Cell
Sha Hu1,2, Wenjing Wang1, Qianfang Hu3
1Department of Pharmacy, Children's Hospital of Soochow University, Suzhou, 215025, China.
Objectives:
Acquired resistance to paclitaxel represents a critical barrier to the effective chemotherapy of non-small cell lung cancer (NSCLC). The present study aimed to elucidate the molecular and pharmacological mechanisms promoting paclitaxel resistance in NSCLC and to explore potential strategies for overcoming this resistance.
Methods:
Here, we report an integrated pharmacological and analytical approach to quantify paclitaxel disposition and overcome resistance in a A549/TAX cell model (paclitaxel-resistant A549 cells).
Results:
Cell counting kit-8 (CCK-8) assay, colony formation, and apoptosis assays confirmed that A549/TAX cells exhibited marked resistance to paclitaxel relative to parental A549 cells. Based on transcriptome profiling by RNA sequencing analysis and validation by western blotting assay, we found that the expression of the ATP-binding cassette subfamily B member 1 (ABCB1) (the encoded protein is termed P-glycoprotein) was significantly upregulated in resistant cells. By using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), we demonstrated that ABCB1 overexpression promotes enhanced efflux of intracellular paclitaxel, thereby lowering its cytotoxic accumulation. Genetic silencing of ABCB1 or pharmacological inhibition with the specific P-glycoprotein modulator elacridar or tariquidar restored intracellular paclitaxel levels, as determined by UPLC-MS/MS, and synergistically decreased cell viability as observed in CCK-8 assay.
Conclusion:
These findings reveal that the ABCB1-mediated drug efflux is a crucial mechanism underlying paclitaxel resistance in NSCLC cells, with UPLC-MS/MS serving as a sensitive analytical method to detect paclitaxel concentration. Inhibition of ABCB1 is a promising therapeutic strategy to resensitize resistant tumor cells to paclitaxel.
Insights
Paclitaxel resistance in non-small cell lung cancer is driven by ABCB1 (P-glycoprotein) efflux. Inhibiting ABCB1 resensitizes cancer cells to paclitaxel, offering a promising therapeutic strategy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Acquired resistance to paclitaxel is a major challenge in non-small cell lung cancer (NSCLC) treatment.
- Understanding the mechanisms of resistance is crucial for developing effective chemotherapy strategies.
Purpose of the Study:
- To investigate the molecular mechanisms of paclitaxel resistance in NSCLC.
- To explore strategies for overcoming paclitaxel resistance in NSCLC.
Main Methods:
- Utilized a paclitaxel-resistant A549/TAX cell model.
- Employed cell counting kit-8 (CCK-8) assay, colony formation, and apoptosis assays for viability assessment.
- Conducted transcriptome profiling (RNA sequencing) and western blotting to identify molecular changes.
- Quantified paclitaxel disposition using ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
Main Results:
- A549/TAX cells showed significant paclitaxel resistance compared to parental cells.
- ATP-binding cassette subfamily B member 1 (ABCB1), also known as P-glycoprotein, was significantly upregulated in resistant cells.
- ABCB1 overexpression led to increased intracellular paclitaxel efflux, reducing its cytotoxic effect.
- Genetic silencing or pharmacological inhibition of ABCB1 restored intracellular paclitaxel levels and decreased cell viability.
Conclusions:
- ABCB1-mediated drug efflux is a key mechanism of paclitaxel resistance in NSCLC.
- UPLC-MS/MS is a sensitive method for measuring paclitaxel concentration.
- Inhibiting ABCB1 shows potential for resensitizing resistant NSCLC cells to paclitaxel therapy.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
Role of Microtubules in Cell Wall Deposition
The Role of Actin and Myosin in Non-muscle Cells
Cell-mediated Immune Responses
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

